Last reviewed · How we verify
Pharmacological cardioversion with Refralon
At a glance
| Generic name | Pharmacological cardioversion with Refralon |
|---|---|
| Also known as | Refralone, Refralon |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter (PHASE4)
- Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation (NA)
- Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: